Megan E. Branda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Megan E. Branda has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Victor M. Montori
Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, USA
20 shared publications - Nilay D. Shah
Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, USA
12 shared publications - Annie LeBlanc
VITAM, Research Center for Sustainable Health, Integrated University Health and Social Services Center (CIUSSS) of the Capitale-Nationale, Laval University, Québec, QC, Canada
8 shared publications - Laurie Pencille
Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA
8 shared publications - Felipe Larios
Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, USA
6 shared publications - Erik P. Hess
Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, USA
5 shared publications
Latest Publications
- 30 September 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (11) , 1239-1246
What Happens after an Incidental Thyroid Nodule? Patterns of Thyroid Ultrasound Use and Downstream Evaluation
Background: Incidental thyroid nodules (ITNs) detected on nonthyroid imaging contribute to thyroid cancer overdiagnosis, largely through downstream evaluation initiated by thyroid ultrasound (TUS). However, TUS follow-up rates for ITNs and their drivers in routine practice remain unclear. We quantified TUS utilization after ITN detection and identified patient, imaging, nodule, and reporting factors associated with this first step in the diagnostic cascade. Methods: We conducted a retrospective cohort study of adults without prior thyroid disease who underwent imaging that incidentally captured the thyroid at Mayo Clinic sites (2017–2023). A validated natural language processing pipeline identified ITNs and extracted nodule characteristics from radiology reports across multiple imaging modalities. The main outcome was the rate of TUS within 180 days after ITN detection. Clinical outcomes, including thyroid biopsy, thyroidectomy, and thyroid cancer diagnosis, were compared between patients who underwent TUS and those who did not. Factors associated with TUS utilization were assessed using multivariable logistic regression with penalized variable selection. Results: Among 115,683 patients who underwent thyroid-capturing imaging, 8426 (7.3%) had an ITN. These patients were predominantly female (64.6%) and White (89.7%), with a mean age of 61.7 years (standard deviation 15.2). Most nodules were detected on computed tomography (80.8%), most commonly from chest imaging (52.3%). Overall, 1677 patients with ITNs (19.9%) underwent TUS. In multivariable analysis, TUS use was independently associated with higher body mass index (odds ratio [OR], 1.20 per 10-unit increase; confidence interval [CI] [1.08–1.33]), nodule size ≥1.5 cm (OR, 1.79; CI [1.52–2.10]), and a radiologist recommendation (OR, 2.51; CI [2.12–2.98]), whereas older age was associated with lower odds of TUS (OR, 0.89 per 10-year increase; CI [0.84–0.93]). Patients undergoing TUS had higher rates of thyroid biopsy, partial thyroidectomy, and total thyroidectomy compared with those without it. All detected thyroid cancers (103 cases) occurred in the TUS group, representing 6.1% of that cohort. Conclusions: One in five patients with ITNs underwent TUS, representing a critical gateway to downstream diagnostic procedures and thyroid cancer detection. Factors associated with TUS utilization highlight opportunities to better define appropriateness of ultrasound after incidental nodule detection and to reduce unnecessary testing and treatment.
- 30 September 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (11) , 1239-1246
What Happens after an Incidental Thyroid Nodule? Patterns of Thyroid Ultrasound Use and Downstream Evaluation
Background: Incidental thyroid nodules (ITNs) detected on nonthyroid imaging contribute to thyroid cancer overdiagnosis, largely through downstream evaluation initiated by thyroid ultrasound (TUS). However, TUS follow-up rates for ITNs and their drivers in routine practice remain unclear. We quantified TUS utilization after ITN detection and identified patient, imaging, nodule, and reporting factors associated with this first step in the diagnostic cascade. Methods: We conducted a retrospective cohort study of adults without prior thyroid disease who underwent imaging that incidentally captured the thyroid at Mayo Clinic sites (2017–2023). A validated natural language processing pipeline identified ITNs and extracted nodule characteristics from radiology reports across multiple imaging modalities. The main outcome was the rate of TUS within 180 days after ITN detection. Clinical outcomes, including thyroid biopsy, thyroidectomy, and thyroid cancer diagnosis, were compared between patients who underwent TUS and those who did not. Factors associated with TUS utilization were assessed using multivariable logistic regression with penalized variable selection. Results: Among 115,683 patients who underwent thyroid-capturing imaging, 8426 (7.3%) had an ITN. These patients were predominantly female (64.6%) and White (89.7%), with a mean age of 61.7 years (standard deviation 15.2). Most nodules were detected on computed tomography (80.8%), most commonly from chest imaging (52.3%). Overall, 1677 patients with ITNs (19.9%) underwent TUS. In multivariable analysis, TUS use was independently associated with higher body mass index (odds ratio [OR], 1.20 per 10-unit increase; confidence interval [CI] [1.08–1.33]), nodule size ≥1.5 cm (OR, 1.79; CI [1.52–2.10]), and a radiologist recommendation (OR, 2.51; CI [2.12–2.98]), whereas older age was associated with lower odds of TUS (OR, 0.89 per 10-year increase; CI [0.84–0.93]). Patients undergoing TUS had higher rates of thyroid biopsy, partial thyroidectomy, and total thyroidectomy compared with those without it. All detected thyroid cancers (103 cases) occurred in the TUS group, representing 6.1% of that cohort. Conclusions: One in five patients with ITNs underwent TUS, representing a critical gateway to downstream diagnostic procedures and thyroid cancer detection. Factors associated with TUS utilization highlight opportunities to better define appropriateness of ultrasound after incidental nodule detection and to reduce unnecessary testing and treatment.
- Open Access
- 3 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e87061
Patient-Centered Summarization Framework for AI Clinical Summarization: Mixed Methods Study
Background: Large language models (LLMs) are increasingly demonstrating the potential to reach human-level performance in generating clinical summaries from patient-clinician conversations. LLMs are usually evaluated against clinical summaries that focus mainly on patients’ biology and not on their biography (eg, preferences, values, wishes, and concerns). To achieve patient-centered care, artificial intelligence clinical summarization must incorporate patient-centered domains, implemented through patient-centered summaries (PCSs). Objective: This study aimed to develop a framework to generate PCS that capture patients’ values, preferences, and wishes while ensuring clinical utility for clinicians, and assess if current open-source LLMs can achieve human-level performance in generating PCS. Methods: We developed a 4-step mixed methods process to define and evaluate PCS. First, 2 patient and public involvement and engagement groups were convened in the United Kingdom (10 patients and 8 clinicians), who participated in semistructured interviews exploring what personal and contextual information should be included in clinical summaries and how it should be structured for clinical use. Second, findings were translated into an annotation guideline, which was used by 8 clinician annotators to generate gold standard PCS from 88 transcribed patient-clinician consultations about the management of atrial fibrillation. Third, 16 consultations were used to iteratively develop and refine a prompt aligned with the annotation guideline. Finally, 5 LLMs (Llama-3.2-3B [Meta AI], Llama-3.1-8B [Meta AI], Mistral-8B [Mistral AI], Gemma-3-4B [Google DeepMind], and Qwen3-8B [Alibaba]) generated summaries from 72 consultations using zero-shot and few-shot prompting, which were evaluated against gold standard PCS using ROUGE-L (Recall-Oriented Understudy for Gisting Evaluation–Longest Common Subsequence) and BERTScore (Bidirectional Encoder Representations from Transformers Score) and assessed for correctness, completeness, conciseness, patient-centeredness, and fluency. Results: Patients emphasized that summaries should include (1) lifestyle routines and daily functioning as indicators of independence or disruption; (2) the presence and role of social support systems, especially during crises; (3) recent life events or stressors, such as trauma, loss, or caregiving demands; and (4) care preferences, values, and communication styles that provide meaning or reflect autonomy. Clinicians sought summaries that included a concise functional baseline, psychosocial context, and emotional cues, preferably in a structured, clinically digestible format. In the 72 consultations (mean age 70, SD 11 y; 32/72, 44.4% female), the best zero-shot performance was observed with Mistral-8B (ROUGE-L 0.189) and Llama-3.1-8B (BERTScore 0.673). The best few-shot prompting was found with 3 examples using Llama-3.1-8B (ROUGE-L 0.206 and BERTScore 0.683). Conclusions: The open-source LLMs we evaluated did not achieve human-level performance in generating PCSs. Without task-specific fine-tuning, current open-source LLMs cannot reach human-level performance in this task. Our framework serves as an innovative guideline for developing gold standard PCS for artificial intelligence clinical tasks.
- 3 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e87061
Open AccessPatient-Centered Summarization Framework for AI Clinical Summarization: Mixed Methods Study
Background: Large language models (LLMs) are increasingly demonstrating the potential to reach human-level performance in generating clinical summaries from patient-clinician conversations. LLMs are usually evaluated against clinical summaries that focus mainly on patients’ biology and not on their biography (eg, preferences, values, wishes, and concerns). To achieve patient-centered care, artificial intelligence clinical summarization must incorporate patient-centered domains, implemented through patient-centered summaries (PCSs). Objective: This study aimed to develop a framework to generate PCS that capture patients’ values, preferences, and wishes while ensuring clinical utility for clinicians, and assess if current open-source LLMs can achieve human-level performance in generating PCS. Methods: We developed a 4-step mixed methods process to define and evaluate PCS. First, 2 patient and public involvement and engagement groups were convened in the United Kingdom (10 patients and 8 clinicians), who participated in semistructured interviews exploring what personal and contextual information should be included in clinical summaries and how it should be structured for clinical use. Second, findings were translated into an annotation guideline, which was used by 8 clinician annotators to generate gold standard PCS from 88 transcribed patient-clinician consultations about the management of atrial fibrillation. Third, 16 consultations were used to iteratively develop and refine a prompt aligned with the annotation guideline. Finally, 5 LLMs (Llama-3.2-3B [Meta AI], Llama-3.1-8B [Meta AI], Mistral-8B [Mistral AI], Gemma-3-4B [Google DeepMind], and Qwen3-8B [Alibaba]) generated summaries from 72 consultations using zero-shot and few-shot prompting, which were evaluated against gold standard PCS using ROUGE-L (Recall-Oriented Understudy for Gisting Evaluation–Longest Common Subsequence) and BERTScore (Bidirectional Encoder Representations from Transformers Score) and assessed for correctness, completeness, conciseness, patient-centeredness, and fluency. Results: Patients emphasized that summaries should include (1) lifestyle routines and daily functioning as indicators of independence or disruption; (2) the presence and role of social support systems, especially during crises; (3) recent life events or stressors, such as trauma, loss, or caregiving demands; and (4) care preferences, values, and communication styles that provide meaning or reflect autonomy. Clinicians sought summaries that included a concise functional baseline, psychosocial context, and emotional cues, preferably in a structured, clinically digestible format. In the 72 consultations (mean age 70, SD 11 y; 32/72, 44.4% female), the best zero-shot performance was observed with Mistral-8B (ROUGE-L 0.189) and Llama-3.1-8B (BERTScore 0.673). The best few-shot prompting was found with 3 examples using Llama-3.1-8B (ROUGE-L 0.206 and BERTScore 0.683). Conclusions: The open-source LLMs we evaluated did not achieve human-level performance in generating PCSs. Without task-specific fine-tuning, current open-source LLMs cannot reach human-level performance in this task. Our framework serves as an innovative guideline for developing gold standard PCS for artificial intelligence clinical tasks.
- Open Access
Comparative value of growth velocity and umbilical artery Doppler for the prediction of adverse perinatal outcomes in growth‐restricted pregnancies
Introduction: Fetal growth restriction (FGR) is associated with an increased risk of neonatal morbidity and mortality. Current diagnostic criteria for FGR do not discriminate between constitutionally small and pathologically restricted fetuses. Following FGR diagnosis, umbilical artery (UA) Doppler is utilized to monitor fetal well‐being, but its limitations have increased interest in investigating growth velocity as an adjunctive tool. The objective of this study is to compare the predictive ability of UA Doppler studies and growth velocity for adverse neonatal outcomes in growth‐restricted fetuses. Methods: This is a secondary analysis of a cohort of pregnancies delivered in a single healthcare network from August 2017 to December 2022, diagnosed antenatally with FGR. The cohort was restricted to those with baseline estimated fetal weight (EFW) between the 3rd and 50th percentiles. All subjects had growth velocity measured (defined as EFW percentile change per week between baseline and subsequent ultrasound). The primary outcome was a composite of neonatal morbidity (neonatal intensive care unit [NICU] admission, low 5‐min Appearance, Pulse, Grimace, Activity, Respiration score [95th percentile; none demonstrated absent or reversed end‐diastolic flow. There was no correlation observed between S/D ratio percentile and growth velocity, suggesting independence. ROC analysis demonstrated that the discriminatory ability of growth velocity was higher across outcomes with areas under the curve (AUC) ranging from 0.65 to 0.69 while AUC for S/D ratio percentiles ranged from 0.51 to 0.53, approximating the performance of chance. Higher growth velocity was significantly associated with reduced odds of the composite outcome (odds ratio [OR], 0.79; 95% confidence interval [CI], 0.69–0.90), and neonatal morbidity (OR, 0.84; 95% CI, 0.73–0.95). S/D ratio percentile was not associated with these outcomes. Conclusion: In pregnancies complicated by growth restriction with forward UA flow, growth velocity outperformed S/D ratio percentile in predicting adverse outcomes. The two tests were independent, indicating that growth velocity may reflect a component of fetal development not captured by UA Doppler. These results suggest that growth velocity could be used in addition to UA Doppler studies for fetal risk assessment, especially in fetuses with forward arterial flow.
Open AccessComparative value of growth velocity and umbilical artery Doppler for the prediction of adverse perinatal outcomes in growth‐restricted pregnancies
Introduction: Fetal growth restriction (FGR) is associated with an increased risk of neonatal morbidity and mortality. Current diagnostic criteria for FGR do not discriminate between constitutionally small and pathologically restricted fetuses. Following FGR diagnosis, umbilical artery (UA) Doppler is utilized to monitor fetal well‐being, but its limitations have increased interest in investigating growth velocity as an adjunctive tool. The objective of this study is to compare the predictive ability of UA Doppler studies and growth velocity for adverse neonatal outcomes in growth‐restricted fetuses. Methods: This is a secondary analysis of a cohort of pregnancies delivered in a single healthcare network from August 2017 to December 2022, diagnosed antenatally with FGR. The cohort was restricted to those with baseline estimated fetal weight (EFW) between the 3rd and 50th percentiles. All subjects had growth velocity measured (defined as EFW percentile change per week between baseline and subsequent ultrasound). The primary outcome was a composite of neonatal morbidity (neonatal intensive care unit [NICU] admission, low 5‐min Appearance, Pulse, Grimace, Activity, Respiration score [95th percentile; none demonstrated absent or reversed end‐diastolic flow. There was no correlation observed between S/D ratio percentile and growth velocity, suggesting independence. ROC analysis demonstrated that the discriminatory ability of growth velocity was higher across outcomes with areas under the curve (AUC) ranging from 0.65 to 0.69 while AUC for S/D ratio percentiles ranged from 0.51 to 0.53, approximating the performance of chance. Higher growth velocity was significantly associated with reduced odds of the composite outcome (odds ratio [OR], 0.79; 95% confidence interval [CI], 0.69–0.90), and neonatal morbidity (OR, 0.84; 95% CI, 0.73–0.95). S/D ratio percentile was not associated with these outcomes. Conclusion: In pregnancies complicated by growth restriction with forward UA flow, growth velocity outperformed S/D ratio percentile in predicting adverse outcomes. The two tests were independent, indicating that growth velocity may reflect a component of fetal development not captured by UA Doppler. These results suggest that growth velocity could be used in addition to UA Doppler studies for fetal risk assessment, especially in fetuses with forward arterial flow.
- 3 March 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43 (12) , 1657-1664
Hypertensive Disorders of Pregnancy: Factors Associated with Multiple Postpartum Blood Pressure Visits
Patients with hypertensive disorders of pregnancy (HDPs) are recommended to attend an early postpartum follow-up visit for blood pressure monitoring. Follow-up frequency for patients with HDPs can vary widely, with some patients requiring multiple office visits. We sought to determine factors associated with multiple postpartum blood pressure visits among patients with HDPs. We retrospectively identified patients with HDPs who delivered at our maternity center in 2019 and compared factors between patients who attended a single blood pressure follow-up appointment without requiring further clinical evaluation for hypertension and patients who required multiple postpartum clinical evaluations for persistent hypertension. Univariate logistic regression models were used to identify factors associated with increased odds of having multiple clinically indicated postpartum visits for blood pressure monitoring. We identified 328 patients with HDPs, of whom 260 (79.3%) attended an initial postpartum blood pressure follow-up appointment and were included in further analyses. Of the 260 patients, 70 (26.9%) had multiple blood pressure visits. Factors associated with multiple blood pressure visits included delivery between 34 and less than 37 weeks of gestation (odds ratio [OR], 3.62; 95% CI, 1.07–12.30), systolic blood pressure before discharge of 140 mm Hg or higher (OR, 5.02; 95% CI, 2.57–9.82), and discharge with blood pressure medication (OR, 3.42; 95% CI, 1.82–6.41). Patients with HDPs who deliver preterm, have persistent hypertension before discharge, or are discharged with antihypertensive medication require continued close postpartum observation and continuity of care.
- 3 March 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43 (12) , 1657-1664
Hypertensive Disorders of Pregnancy: Factors Associated with Multiple Postpartum Blood Pressure Visits
Patients with hypertensive disorders of pregnancy (HDPs) are recommended to attend an early postpartum follow-up visit for blood pressure monitoring. Follow-up frequency for patients with HDPs can vary widely, with some patients requiring multiple office visits. We sought to determine factors associated with multiple postpartum blood pressure visits among patients with HDPs. We retrospectively identified patients with HDPs who delivered at our maternity center in 2019 and compared factors between patients who attended a single blood pressure follow-up appointment without requiring further clinical evaluation for hypertension and patients who required multiple postpartum clinical evaluations for persistent hypertension. Univariate logistic regression models were used to identify factors associated with increased odds of having multiple clinically indicated postpartum visits for blood pressure monitoring. We identified 328 patients with HDPs, of whom 260 (79.3%) attended an initial postpartum blood pressure follow-up appointment and were included in further analyses. Of the 260 patients, 70 (26.9%) had multiple blood pressure visits. Factors associated with multiple blood pressure visits included delivery between 34 and less than 37 weeks of gestation (odds ratio [OR], 3.62; 95% CI, 1.07–12.30), systolic blood pressure before discharge of 140 mm Hg or higher (OR, 5.02; 95% CI, 2.57–9.82), and discharge with blood pressure medication (OR, 3.42; 95% CI, 1.82–6.41). Patients with HDPs who deliver preterm, have persistent hypertension before discharge, or are discharged with antihypertensive medication require continued close postpartum observation and continuity of care.
- Open Access
Videographic Analysis of an Intervention to Improve Patient-Centered Care for People Living with Type 2 Diabetes: the QBSAFE Randomized Trial
Background The self-management of type 2 diabetes (T2D) typically requires enacting various lifestyle changes, which can challenge people living with T2D. Clinical encounters between people with T2D and their clinicians, however, are often focused on metabolic management, leaving less time available for other self-management topics. The QBSAFE cards help patients articulate aspects of their experience with diabetes and prioritize issues for discussion. Methods This report details secondary outcomes of a randomized controlled trial; primary outcomes are reported elsewhere. All data was collected at Fair Haven Community Health Care, a federally qualified primary care clinic. 11 clinicians were randomly assigned to provide either usual care or usual care with QBSAFE cards to 155 of their patients with type 2 diabetes and hemoglobin A1c >8%. All patient encounters were video recorded for analysis. Patients and clinicians were not blinded to arm allocation but were kept unaware of the specific aims of the trial. Encounter video reviewers were blinded to arm allocation, but not to specific aims of the trial. The outcomes of interest for this report were the extent to which the QBSAFE cards were used as intended, their effect on the topics of discussion, and whether they enabled clinicians to notice and respond to each patient's situation; comparisons between arms were conducted by a linear mixed model with fixed effect of arm and cluster effect of clinician, analyzed in both intent-to-treat and per-protocol populations. Findings 12 patients were excluded post-randomization (A1c <8%). Of 143 eligible patients, 137 encounters (65 in the usual care arm, 72 in QBSAFE) yielded evaluable videos. QBSAFE was used as intended in 61 (85%) QBSAFE arm encounters. Conversations about burden of treatment related to non-pharmacological interventions (17 vs 33, p= 0.04) and taking medications (11 vs 33, p= 0.0008) and about the patient's challenging environment (2 vs 10, p= 0.04) were more prevalent in the QBSAFE group. There was no difference in the rate of conversations about metabolic management or of new care plans as a result of conversations between groups. Interpretation While there was a difference in the types of conversations observed between the two study arms, this difference was small and only apparent in a few domains. Future work could aim to modify the QBSAFE cards to more effectively stimulate patient-centered discussions and to further prepare clinicians to respond to a variety of issues raised during the clinical visit. Funding 3 This work was supported by funding from the
Open AccessVideographic Analysis of an Intervention to Improve Patient-Centered Care for People Living with Type 2 Diabetes: the QBSAFE Randomized Trial
Background The self-management of type 2 diabetes (T2D) typically requires enacting various lifestyle changes, which can challenge people living with T2D. Clinical encounters between people with T2D and their clinicians, however, are often focused on metabolic management, leaving less time available for other self-management topics. The QBSAFE cards help patients articulate aspects of their experience with diabetes and prioritize issues for discussion. Methods This report details secondary outcomes of a randomized controlled trial; primary outcomes are reported elsewhere. All data was collected at Fair Haven Community Health Care, a federally qualified primary care clinic. 11 clinicians were randomly assigned to provide either usual care or usual care with QBSAFE cards to 155 of their patients with type 2 diabetes and hemoglobin A1c >8%. All patient encounters were video recorded for analysis. Patients and clinicians were not blinded to arm allocation but were kept unaware of the specific aims of the trial. Encounter video reviewers were blinded to arm allocation, but not to specific aims of the trial. The outcomes of interest for this report were the extent to which the QBSAFE cards were used as intended, their effect on the topics of discussion, and whether they enabled clinicians to notice and respond to each patient's situation; comparisons between arms were conducted by a linear mixed model with fixed effect of arm and cluster effect of clinician, analyzed in both intent-to-treat and per-protocol populations. Findings 12 patients were excluded post-randomization (A1c <8%). Of 143 eligible patients, 137 encounters (65 in the usual care arm, 72 in QBSAFE) yielded evaluable videos. QBSAFE was used as intended in 61 (85%) QBSAFE arm encounters. Conversations about burden of treatment related to non-pharmacological interventions (17 vs 33, p= 0.04) and taking medications (11 vs 33, p= 0.0008) and about the patient's challenging environment (2 vs 10, p= 0.04) were more prevalent in the QBSAFE group. There was no difference in the rate of conversations about metabolic management or of new care plans as a result of conversations between groups. Interpretation While there was a difference in the types of conversations observed between the two study arms, this difference was small and only apparent in a few domains. Future work could aim to modify the QBSAFE cards to more effectively stimulate patient-centered discussions and to further prepare clinicians to respond to a variety of issues raised during the clinical visit. Funding 3 This work was supported by funding from the
- Open Access
QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes
Background: Effective interventions are needed to support co-creation of diabetes care plans that fit patients’ lives. We evaluated the QBSafe agenda-setting kit (14 conversation cards) for its impact on care fit and glycemic control when added to usual primary care. Methods: This single-center, clinician-level cluster-randomized, open-label trial was conducted at a federally qualified health center in New Haven, Connecticut ( ClinicalTrials.gov NCT05553912 ). Clinicians and their patients with type 2 diabetes and HbA1c >8% were randomized 1:1 to usual care with or without QBSafe cards. In the intervention arm, patients selected up to 3 cards highlighting concerns about life with diabetes prior to their visit. Primary outcomes were change at 6 months in care fit (Illness Intrusiveness Ratings Scale, IIRS) and HbA1c, analyzed by intention to treat. Secondary outcomes were treatment burden (Treatment Burden Questionnaire, TBQ) and diabetes distress (Diabetes Distress Scale, DDS), and satisfaction with visits. Results: Between February 2023 and July 2024, 143 participants (mean age 56 years; 61% female; 73% Hispanic; mean HbA1c 10%) were enrolled: 74 received usual care with QBSafe, 69 usual care alone. At 6 months, there were no significant between-arm differences in changes in IIRS (−3.9 [95% CI -10.4, 2.6]), HbA1c (−0.2% [95% CI -0.9, 0.5]), TBQ (1.0 [95% CI -16.6, 18.6]), or DDS (−0.1 [95% CI -0.4, 0.2]). Clinicians reported greater satisfaction when using QBSafe. Patient satisfaction was high and did not differ across arms. Conclusions: QBSafe cards improved clinician satisfaction but did not improve care fit or glycemic control. Future tools should focus on helping clinicians respond effectively to patient-identified challenges.
Open AccessQBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes
Background: Effective interventions are needed to support co-creation of diabetes care plans that fit patients’ lives. We evaluated the QBSafe agenda-setting kit (14 conversation cards) for its impact on care fit and glycemic control when added to usual primary care. Methods: This single-center, clinician-level cluster-randomized, open-label trial was conducted at a federally qualified health center in New Haven, Connecticut ( ClinicalTrials.gov NCT05553912 ). Clinicians and their patients with type 2 diabetes and HbA1c >8% were randomized 1:1 to usual care with or without QBSafe cards. In the intervention arm, patients selected up to 3 cards highlighting concerns about life with diabetes prior to their visit. Primary outcomes were change at 6 months in care fit (Illness Intrusiveness Ratings Scale, IIRS) and HbA1c, analyzed by intention to treat. Secondary outcomes were treatment burden (Treatment Burden Questionnaire, TBQ) and diabetes distress (Diabetes Distress Scale, DDS), and satisfaction with visits. Results: Between February 2023 and July 2024, 143 participants (mean age 56 years; 61% female; 73% Hispanic; mean HbA1c 10%) were enrolled: 74 received usual care with QBSafe, 69 usual care alone. At 6 months, there were no significant between-arm differences in changes in IIRS (−3.9 [95% CI -10.4, 2.6]), HbA1c (−0.2% [95% CI -0.9, 0.5]), TBQ (1.0 [95% CI -16.6, 18.6]), or DDS (−0.1 [95% CI -0.4, 0.2]). Clinicians reported greater satisfaction when using QBSafe. Patient satisfaction was high and did not differ across arms. Conclusions: QBSafe cards improved clinician satisfaction but did not improve care fit or glycemic control. Future tools should focus on helping clinicians respond effectively to patient-identified challenges.
- Open Access
- 13 May 2025
- Published by Cold Spring Harbor Laboratory in medRxiv
Development of the TBQ+D: A Novel Patient-Reported Measure of The Burden of Digital Care
Background Patients with diabetes often manage complex treatment regimens that increasingly include the use of digital medicine tools. While several instruments measure treatment burden, none capture the specific burden introduced by digital medicine tools used in self-care. Development of patient reported measures to capture digital treatment burden are needed to assess the lived experiences and challenges patients face when using digital medicine tools. Objective To engage patients and clinical experts in adapting an existing measure of treatment burden—the Treatment Burden Questionnaire (TBQ). The adapted instrument underwent cognitive testing and refinements to ensure it could capture the burden of using digital medicine tools in the self-management and care of diabetes. Methods This two-phase study was conducted with adults with diabetes and other chronic conditions at the Division of Endocrinology at Mayo Clinic in Rochester, Minnesota. First, we mapped themes from prior concept elicitation interviews to existing TBQ items to identify content gaps related to digital burden. Based on these gaps, the study team and expert panel followed an item development guide to generate new items and adapt existing ones to better reflect the workload and burdens imposed by digital medicine tools. The resulting adapted instrument underwent three rounds of cognitive testing with adult patients living with diabetes, using a think-aloud protocol to assess clarity, relevance, and comprehensiveness. Results of cognitive testing informed iterative refinements across three rounds of interviews, leading to improved clarity, reduced redundancy, and improved relevance of items. Results The final TBQ+D retained the structure of the original 15-item TBQ and included 8 new items and modified 8 extant ones to capture burden of digital care (e.g., syncing issues, discomfort from sensors, and device malfunctions). Cognitive testing demonstrated strong content relevance and patient comprehension. Conclusion The TBQ+D appears able to measure digital treatment burden in patients with diabetes. Planned next steps include field testing the instrument to test validity hypotheses, and if successful, extending this evaluation to diverse populations and clinical and research settings.
- 13 May 2025
- Published by Cold Spring Harbor Laboratory in medRxiv
Open AccessDevelopment of the TBQ+D: A Novel Patient-Reported Measure of The Burden of Digital Care
Background Patients with diabetes often manage complex treatment regimens that increasingly include the use of digital medicine tools. While several instruments measure treatment burden, none capture the specific burden introduced by digital medicine tools used in self-care. Development of patient reported measures to capture digital treatment burden are needed to assess the lived experiences and challenges patients face when using digital medicine tools. Objective To engage patients and clinical experts in adapting an existing measure of treatment burden—the Treatment Burden Questionnaire (TBQ). The adapted instrument underwent cognitive testing and refinements to ensure it could capture the burden of using digital medicine tools in the self-management and care of diabetes. Methods This two-phase study was conducted with adults with diabetes and other chronic conditions at the Division of Endocrinology at Mayo Clinic in Rochester, Minnesota. First, we mapped themes from prior concept elicitation interviews to existing TBQ items to identify content gaps related to digital burden. Based on these gaps, the study team and expert panel followed an item development guide to generate new items and adapt existing ones to better reflect the workload and burdens imposed by digital medicine tools. The resulting adapted instrument underwent three rounds of cognitive testing with adult patients living with diabetes, using a think-aloud protocol to assess clarity, relevance, and comprehensiveness. Results of cognitive testing informed iterative refinements across three rounds of interviews, leading to improved clarity, reduced redundancy, and improved relevance of items. Results The final TBQ+D retained the structure of the original 15-item TBQ and included 8 new items and modified 8 extant ones to capture burden of digital care (e.g., syncing issues, discomfort from sensors, and device malfunctions). Cognitive testing demonstrated strong content relevance and patient comprehension. Conclusion The TBQ+D appears able to measure digital treatment burden in patients with diabetes. Planned next steps include field testing the instrument to test validity hypotheses, and if successful, extending this evaluation to diverse populations and clinical and research settings.
- Open Access
- 15 April 2024
- Published by Wiley in Learning Health Systems
- Vol. 8 (S1) , e10418
Healthcare systems collaborating to implement a shared decision‐making tool in the electronic health record and build evidence on its adoption and use
Introduction: Shared decision‐making (SDM) is a method of care by which patients and clinicians work together to co‐create a plan of care. Electronic health record (EHR) integration of SDM tools may increase adoption of SDM. We conducted a “lightweight” integration of a freely available electronic SDM tool, CV Prevention Choice, within the EHRs of three healthcare systems. Here, we report how the healthcare systems collaborated to achieve integration.Methods: This work was conducted as part of a stepped wedge randomized pragmatic trial. CV Prevention Choice was developed using guidelines for HTML5‐based web applications. Healthcare systems integrated the tool in their EHR using documentation the study team developed and refined with lessons learned after each system integrated the electronic SDM tool into their EHR. CV Prevention Choice integration populates the tool with individual patient data locally without sending protected health information between the EHR and the web. Data abstraction and secure transfer systems were developed to manage data collection to assess tool implementation and effectiveness outcomes.Results: Time to integrate CV Prevention Choice in the EHR was 12.1 weeks for the first system, 10.4 weeks for the second, and 9.7 weeks for the third. One system required two 1‐hour meetings with study team members and two healthcare systems required a single 1‐hour meeting. Healthcare system information technology teams collaborated by sharing information and offering improvements to documentation. Challenges included tracking CV Prevention Choice use for reporting and capture of combination medications. Data abstraction required refinements to address differences in how each healthcare system captured data elements.Conclusion: Targeted documentation on tool features and resource mapping supported collaboration of IT teams across healthcare systems, enabling them to integrate a web‐based SDM tool with little additional research team effort or oversight. Their collaboration helped overcome difficulties integrating the web application and address challenges to data harmonization for trial outcome analyses.
- 15 April 2024
- Published by Wiley in Learning Health Systems
- Vol. 8 (S1) , e10418
Open AccessHealthcare systems collaborating to implement a shared decision‐making tool in the electronic health record and build evidence on its adoption and use
Introduction: Shared decision‐making (SDM) is a method of care by which patients and clinicians work together to co‐create a plan of care. Electronic health record (EHR) integration of SDM tools may increase adoption of SDM. We conducted a “lightweight” integration of a freely available electronic SDM tool, CV Prevention Choice, within the EHRs of three healthcare systems. Here, we report how the healthcare systems collaborated to achieve integration.Methods: This work was conducted as part of a stepped wedge randomized pragmatic trial. CV Prevention Choice was developed using guidelines for HTML5‐based web applications. Healthcare systems integrated the tool in their EHR using documentation the study team developed and refined with lessons learned after each system integrated the electronic SDM tool into their EHR. CV Prevention Choice integration populates the tool with individual patient data locally without sending protected health information between the EHR and the web. Data abstraction and secure transfer systems were developed to manage data collection to assess tool implementation and effectiveness outcomes.Results: Time to integrate CV Prevention Choice in the EHR was 12.1 weeks for the first system, 10.4 weeks for the second, and 9.7 weeks for the third. One system required two 1‐hour meetings with study team members and two healthcare systems required a single 1‐hour meeting. Healthcare system information technology teams collaborated by sharing information and offering improvements to documentation. Challenges included tracking CV Prevention Choice use for reporting and capture of combination medications. Data abstraction required refinements to address differences in how each healthcare system captured data elements.Conclusion: Targeted documentation on tool features and resource mapping supported collaboration of IT teams across healthcare systems, enabling them to integrate a web‐based SDM tool with little additional research team effort or oversight. Their collaboration helped overcome difficulties integrating the web application and address challenges to data harmonization for trial outcome analyses.